Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT00078338 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00078338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00078338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Lead sponsor
EMD Serono
Phase
Phase 4
Overall status
Completed
Start date
February 16, 2004
Completion date
November 28, 2006
Enrollment
764 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis